Guidelines Detailed Commission guidelines on good
30 to investigational medicinal products, not specifically mentioned in these guidelines, are 31 Part I, Chapters 2, and 6, and Part III. 1 Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (OJ L 158, 27.5.2014, p. 1).
Download Guidelines Detailed Commission guidelines on good
Information
Domain:
Source:
Link to this page:
Documents from same domain
Russia - Country Page - European Commission
ec.europa.euLast update: November 2017 1 Russia - Country Page 1. Available national programmes or funds that could provide support to Russian Horizon 2020 participants
Evaluation of Innovation Activities - European …
ec.europa.euJune 2012 Evaluation of Innovation Activities Guidance on methods and practices Evaluation of Innovation Activities Guidance on methods and practices
EN Horizon 2020 Work Programme 2018-2020
ec.europa.euHorizon 2020 - Work Programme 2018-2020 Health, demographic change and wellbeing Part 8 - Page 3 of 124 SC1-BHC-19-2019: Implementation research for maternal and child health..... 41
H2020 Programme - ec.europa.eu
ec.europa.eu5 Your policy should also: reflect the current state of consortium agreements on data management be consistent with exploitation and Intellectual Property Rights (IPR)
International Accounting Standard 39 Financial …
ec.europa.euEC staff consolidated version as of 18 February 2011 FOR INFORMATION PURPOSES ONLY 1 International Accounting Standard 39 Financial …
International Financial Reporting Standard 1
ec.europa.euEC staff consolidated version as of 21/06/2012, ²² EN – EU IFRS 1 FOR INFORMATION PURPOSES ONLY International Financial Reporting Standard 1
International Financial Reporting Standard 3 …
ec.europa.euEC staff consolidated version as of 18 February 2011 FOR INFORMATION PURPOSES ONLY 1 International Financial Reporting Standard 3 Business Combinations
Literature review Teachers’ core ... - ec.europa.eu
ec.europa.eu© European Commission 1 EUROPEAN COMMISSION Directorate-General for Education and Culture Lifelong learning: policies and …
WP243 ANNEX - FREQUENTLY ASKED QUESTIONS …
ec.europa.euWP243 ANNEX - FREQUENTLY ASKED QUESTIONS The objective of this annex is to answer, in a simplified and easy-to-read format, some of the key questions that organisations may have regarding the new requirements under the GDPR to appoint a
Teachers’ continuing professional development
ec.europa.eu© European Commission 2 Literature review Quality in Teachers’ continuing professional developmenti 1. Teacher Professional Development: the …
Related documents
DADI-PMS Webinar Agenda Variations Form for Human …
esubmission.ema.europa.euDADI-PMS Webinar Agenda – ‘Variations Form for Human Medicinal Products - What will happen at Go-Live’ 16 May 2022, 10:00 – 12:00 Central European Time (CET) Webinar: WebEx Item Agenda Time 1. Welcome / Introduction Joris Wiemer, Change Management Lead, EMA 10:00-10:05 5 mins 2. Web forms as part of the Data-centric Target Operating Model
Guideline on the environmental risk assessment of medicinal …
www.ema.europa.eu58 hazards of human medicinal products (HMP). It specifies the scope and legal basis for assessment. It 59 outlines general considerations and the recommended step- wise procedure of assessment. The general 60 outline of the Environmental Risk Assessment Report is …
Guideline on Risk Assessment of Medicinal Products on …
www.ema.europa.euIntegration of animal and human data to assess the risks of the use of medicinal products during pregnancy is a critical task, which is aimed at reducing the induction of birth defects as far as possible. In this document the process of assessment of non-clinical, i.e. animal data is described, followed by guidance on the assessment of human data.
Medicinal products in the European Union
www.europarl.europa.euThe first Community rules on medicinal products for human use date back 50 years. Beginning with Council Directive 65/65/EEC,6 which was introduced in the wake of the thalidomide disaster, the then-European Economic Community began developing structured legislation. The legal framework has since been continuously updated.